CD8+ T-cell responses identify beta-cell autoimmunity in human type 1 diabetes

Area of Science:

• Immunology
• Endocrinology
• Autoimmunity

Background:

• Type 1 diabetes pathogenesis involves T-cells, but their detection is challenging.
• CD8+ T-cells are critical in mouse models and likely in human type 1 diabetes.
• Existing CD4+ T-cell assays have limited success.

Purpose of the Study:

• To develop a sensitive assay for detecting and quantifying islet-specific CD8+ T-cells.
• To identify potential biomarkers for type 1 diabetes autoimmunity.
• To explore new avenues for type 1 diabetes prediction and prevention.

Main Methods:

• Development of an islet-specific CD8+ T-cell interferon-gamma enzyme-linked immunospot (ISL8Spot) assay.
• Utilized HLA-A2-restricted beta-cell epitopes from preproinsulin, GAD, and IGRP.
• Direct ex vivo detection and quantification without cell expansion, using fresh or frozen samples.

Main Results:

• The ISL8Spot assay accurately distinguishes new-onset diabetic from healthy samples (86% sensitivity, 91% specificity) using five epitopes.
• Assay sensitivity reached 100% when combined with antibody determinations.
• Demonstrated ability to detect and quantify beta-cell-reactive CD8+ T-cells directly ex vivo.

Conclusions:

• The ISL8Spot assay provides a novel tool for detecting beta-cell autoimmunity in type 1 diabetes.
• Combining CD8+ T-cell detection with antibody measurements enhances diagnostic accuracy.
• This assay holds promise for preclinical diagnosis, immune surrogate endpoints, and prevention strategies.